Quick Answer
Liminatus Pharma, Inc. reported Research And Development Expense of $2.69 million for the year ending 2024.
- This data is from Liminatus Pharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 31, 2026.
- XBRL data for this metric is available from 2024 to 2024 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2024: $714.1 thousand | Q3 2024: $357.1 thousand.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: